Is It Better to Have Prostate Removed or Radiation?

For men with localized prostate cancer, surgery and radiation produce remarkably similar survival rates. The landmark ProtecT trial, which followed men for 15 years, found that prostate cancer death occurred in roughly 2 to 3 percent of patients regardless of whether they had their prostate removed, received radiation, or were monitored without immediate treatment. The real differences between the two approaches lie in their side-effect profiles and what happens if the cancer comes back. Choosing between them is less about which treatment is “better” in the abstract and more about which set of trade-offs fits your body, your priorities, and your specific cancer.

What the Survival Numbers Actually Show

The strongest evidence comes from the ProtecT trial, a randomized study of over 1,600 men with localized prostate cancer assigned to active monitoring, surgery, or radiation. After 15 years, prostate cancer deaths were almost identical across all three groups: about 3.1 percent in the monitoring group, 2.2 percent in the surgery group, and 2.9 percent in the radiation group, with no statistically significant difference.¹ Death from any cause was also similar. Where surgery and radiation did outperform monitoring was in reducing metastases and clinical progression: roughly 5 percent of treated men developed metastases versus about 9 percent of those monitored.

Observational studies tell a slightly different story because they include older, sicker patients who are more likely to receive radiation than surgery. One large population-based study found that surgery was associated with better overall survival than radiation, but prostate cancer-specific survival was statistically the same between the two groups.² Another analysis using propensity-score matching reported that men who had surgery had roughly 89 percent ten-year overall survival, compared with about 82-83 percent for men receiving external beam radiation or brachytherapy.³ But these gaps largely reflect the fact that healthier men tend to be steered toward surgery in the first place. When you correct for that selection bias, the cancer-specific survival gap narrows or disappears.

The Side-Effect Trade-Off

This is where the two treatments genuinely diverge, and it is often the deciding factor. Surgery hits urinary continence and sexual function harder, while radiation is more likely to cause bowel problems. Neither treatment is side-effect free, and neither is categorically gentler.

After prostate removal, urinary incontinence is a common early problem. A large study tracking patient-reported outcomes found that men who had surgery scored significantly worse on urinary continence than men who had radiation or active surveillance, with that gap persisting at three years.⁴ Radiation had almost no measurable effect on continence. In the ProtecT trial, surgery had the greatest negative effect on both sexual function and urinary continence, and while some recovery occurred over time, the surgery group remained worse off in these domains throughout the study period.⁵ Radiation did affect sexual function, hitting its worst point at about six months, but then partially recovered and stabilized.

When it comes to erectile function specifically, brachytherapy (radioactive seed implants) tends to preserve it best, followed by external beam radiation, with surgery at the bottom. After correcting for age and baseline function, one study found that brachytherapy patients scored meaningfully higher on erectile function questionnaires than surgery patients.⁶ However, when surgery included careful nerve-sparing technique, the gap between surgery and brachytherapy shrank and lost statistical significance. That detail matters: surgical technique and surgeon experience can meaningfully change your odds of preserving erections.

Bowel Problems and Secondary Cancer Risk With Radiation

Radiation’s signature side effect is bowel irritation: looser stools, urgency, rectal bleeding, and in some cases proctitis (inflammation of the rectal lining). Modern, more precisely targeted techniques have reduced these problems. A comparison of image-guided intensity-modulated radiation (IG-IMRT) against older 3D-conformal techniques found that the five-year rate of significant bowel toxicity dropped from about 38 percent to 25 percent with the newer approach.⁷ Proctitis and increased stool frequency both fell substantially. That said, some degree of bowel change remains a real possibility even with state-of-the-art equipment.

A concern unique to radiation is the small but real increase in second cancers developing years later. Radiation scatter can reach the bladder, rectum, and surrounding tissues. Men treated with external beam radiation had roughly double the rate of bladder cancer compared with men treated with surgery, and the rate of rectal cancer was also elevated.⁸ A large study using SEER cancer registry data confirmed this pattern: bladder cancer occurred in about 1.8 percent of radiation-treated men versus 1.1 percent of surgery-treated men, with smaller absolute increases in leukemia, rectal cancer, and lymphoma.⁹ These radiation-associated bladder cancers also tend to be more aggressive when they do occur.¹⁰ The absolute risk remains low in percentage terms, but it is worth factoring in, especially for younger men who have decades of life ahead.

How Cancer Risk Level Changes the Equation

Prostate cancer is not one disease. A man with a small, low-grade tumor faces an entirely different situation from a man with aggressive, high-grade cancer that is starting to extend beyond the prostate capsule. The risk category, generally based on PSA level, Gleason score, and clinical stage, shifts which treatment makes more sense.

For low-risk cancers, active surveillance (discussed in the next section) is increasingly the preferred first step, because the cancer itself may never cause harm. When active treatment is chosen for low-risk disease, both surgery and radiation deliver excellent cancer control, and the choice usually comes down to the side-effect profile you would rather live with.

For intermediate-risk cancers, the decision is more nuanced. Both treatments work well, but the addition of short-term hormone therapy alongside radiation can improve outcomes. The ProtecT trial, which enrolled mostly men with intermediate-risk disease, showed nearly identical long-term cancer mortality across treatment groups.

For high-risk cancers, the calculus shifts again. Radiation is typically combined with long-term hormone therapy, and a meta-analysis found that this combination significantly improved cancer-specific survival and disease-free survival compared to radiation alone.¹¹ Surgery remains an option for high-risk disease, though some surgeons are more cautious about offering it when the cancer appears to extend beyond the prostate. Interestingly, one of the potential advantages of surgery is that it produces a tissue specimen that gives pathologists a complete picture of the cancer, sometimes revealing that the disease was more or less aggressive than biopsy suggested.

Active Surveillance as a Third Path

For men with low-risk prostate cancer, the honest answer to “surgery or radiation?” may be “neither, at least not yet.” Active surveillance means monitoring the cancer with regular PSA tests, imaging, and repeat biopsies, stepping in with treatment only if the cancer shows signs of progressing. This is not the same as doing nothing; it is structured watchfulness.

A decision analysis found that for a 65-year-old man in average health with low-risk cancer, surgery added only about 0.3 years of life expectancy compared with surveillance, while adding about 1.6 additional years of living with impotence or incontinence.¹² When quality-adjusted life years were calculated, surveillance came out slightly ahead. Older age and poorer baseline health tilted the analysis even more in surveillance’s favor.

One concern that keeps some men off surveillance is anxiety. But a systematic review of 34 studies involving over 12,000 patients found that anxiety and depression rates among men on active surveillance were either the same as or lower than rates in the general population.¹³ While about 29 percent of men reported mild prostate cancer-related anxiety in the first year, most adjusted within two years. The ProtecT trial found no significant differences in anxiety or cancer-related quality of life between monitored men and those who had immediate treatment.

Does Robotic Surgery Change the Picture?

Most prostate removals today are done with robotic assistance rather than through traditional open surgery. Men often assume the robot produces better outcomes, and there is some evidence that it does, but less than the marketing suggests.

A randomized trial directly comparing robotic and open prostatectomy found that urinary and sexual function scores were essentially identical at 6, 12, and 24 months after surgery.¹⁴ A longer-term follow-up study at 8 years found similar continence rates between the two approaches (about 27 versus 29 percent still reporting incontinence) but a modest advantage for the robotic approach in erectile function and, in the high-risk subgroup, in cancer-specific mortality and positive surgical margin rates.¹⁵ The robotic approach does generally mean less blood loss, shorter hospital stays, and faster initial recovery. But if you are choosing between surgery and radiation, the surgical technique is a secondary question. The more fundamental choice is whether you want the prostate out or treated in place.

Modern Radiation Techniques and Options

Radiation is not a single treatment. External beam radiation, brachytherapy, and stereotactic body radiation (SBRT) all deliver radiation differently, with different side-effect profiles and time commitments.

External beam radiation has traditionally required daily visits over seven to nine weeks. Newer hypofractionated schedules and SBRT have compressed this to five treatments over one to two weeks. SBRT has been found not inferior to conventional external beam therapy in randomized trials and compares favorably to brachytherapy, with the advantage of less acute urinary toxicity and potentially less sexual impairment.¹⁶ Brachytherapy, which places radioactive seeds directly into the prostate, is typically a single-day outpatient procedure for low-dose-rate versions, or several sessions for high-dose-rate. For men with low or favorable intermediate-risk cancer, brachytherapy alone often suffices. For higher-risk cancers, it is frequently combined with external beam radiation and hormone therapy.

What Happens If Cancer Comes Back

One underappreciated difference between surgery and radiation is the flexibility you have if the cancer recurs. After surgery, if PSA starts rising again, radiation can be given to the prostate bed as salvage therapy. A systematic review found that early salvage radiation after prostatectomy remains a viable strategy, and for men with relatively favorable pathology such as low-grade tumors with positive surgical margins, monitoring PSA before deciding on salvage radiation is also reasonable.¹⁷

After radiation, salvage options exist but are trickier. Salvage prostatectomy after radiation is technically more difficult and carries higher complication rates than primary surgery, because radiation changes the tissue planes surgeons rely on. Other salvage approaches, including cryotherapy, focal therapy, and high-intensity focused ultrasound, are available but have less long-term data. This asymmetry in salvage flexibility is one reason some urologists lean toward recommending surgery first for younger men: if radiation is needed later, it can be added, but the reverse sequence is harder.

Age, Health, and Who Gets What

In practice, age heavily influences which treatment doctors recommend, though research suggests it probably should not be the primary factor. A large study found that curative treatments were offered less often as patients aged, but that comorbidity scores had no independent impact on whether a curative approach was selected.¹⁸ The result was a 20 percent overtreatment rate in low-risk patients (men who probably would have done fine on surveillance) and a 16 percent undertreatment rate in older patients over 75 who were otherwise healthy enough for curative treatment. A separate analysis emphasized that treatment decisions should be based on disease risk and life expectancy rather than age alone.¹⁹

The practical upshot: if you are 72 and healthy, do not let anyone dismiss curative treatment solely because of your age. And if you are 58 with serious heart disease or diabetes, the side effects and recovery demands of surgery may matter more than your chronological youth would suggest. Life expectancy and overall health are the right lenses, not the number on your birthday.

Treatment Regret and What Drives It

What men wish they had done differently offers a revealing window into the surgery-versus-radiation question. Five years after diagnosis, about 16 percent of men who had surgery reported treatment-related regret, compared with 11 percent of radiation patients and 7 percent of men on active surveillance.²⁰ Surgery was associated with more than double the odds of regret compared with active surveillance, while radiation was not significantly different from surveillance after adjusting for baseline differences.

The study found that the treatment modality itself was not independently driving regret once you accounted for functional outcomes. What predicted regret most strongly was sexual dysfunction. Men whose side effects turned out worse than expected, and men who felt the treatment was less effective than promised, were far more likely to wish they had chosen differently. A systematic review of regret studies confirmed this pattern: sexual and urinary side effects were the most common reasons for regret, and regret levels were generally higher after surgery than after radiation.²¹ A separate meta-analysis added that men who felt less involved in the decision-making process were also more prone to regret.²²

The implication is clear: the more realistically you understand the likely side effects before choosing, and the more actively you participate in the decision, the less likely you are to regret your choice regardless of which treatment you pick.

When Hormone Therapy Enters the Picture

Hormone therapy, also called androgen deprivation therapy (ADT), is frequently combined with radiation for intermediate- and high-risk cancers. It is less commonly used alongside surgery. ADT suppresses testosterone to slow cancer growth, and it meaningfully improves outcomes when paired with radiation for higher-risk disease. But it comes with its own burden.

Long-term ADT increases the risk of bone fractures, diabetes, heart disease, and dementia. A large analysis found that among these side effects, bone fracture risk was the most elevated, followed by diabetes and cognitive decline, with risk climbing as total hormone therapy exposure increased.²³ One reassuring finding is that adding hormone therapy to radiation does not appear to make the radiation-specific quality-of-life effects worse: a study tracking recovery across six quality-of-life domains found no significant delay in returning to baseline when ADT was added.²⁴ The hormone therapy side effects occur on top of, not multiplied by, the radiation side effects.

This matters for the surgery-versus-radiation comparison because radiation for higher-risk cancers almost always includes months or years of hormone therapy, and the side effects of that combined regimen should be weighed against the surgical side-effect profile. It is not a simple “radiation versus surgery” comparison at that point; it is “radiation plus hormone therapy versus surgery, possibly followed by radiation if cancer returns.”

How Advanced Imaging and Genomic Tests Are Changing Decisions

One reason the surgery-versus-radiation decision has historically been so difficult is that doctors were making it with imperfect information about where exactly the cancer was and how aggressive it truly was. That is starting to change.

PSMA PET scans, which light up prostate cancer cells throughout the body, have altered management in a meaningful fraction of patients. In one study of men with intermediate- or high-risk prostate cancer, PSMA PET produced new information in about a third of patients compared with conventional imaging, and in roughly a quarter of cases, that new information changed the treatment plan, either to a different modality entirely or by adjusting treatment details like radiation field size.²⁵

On the genomic side, tissue-based tests that analyze gene activity in biopsy samples can now predict the likelihood of metastasis and cancer-specific death. One such classifier was validated in men treated with either radiation or surgery and was able to predict metastasis and prostate cancer-specific mortality from diagnostic biopsy specimens.²⁶ For a man whose genomic score suggests very low metastatic risk, active surveillance becomes more defensible. For one whose score flags high risk despite seemingly moderate clinical features, aggressive treatment, and the specific type of aggressive treatment, becomes a more urgent conversation. These tools do not eliminate the surgery-versus-radiation dilemma, but they sharpen it by giving both patient and doctor a clearer picture of what the cancer is actually likely to do.